NCT03141918

Brief Summary

Among the many changes associated with the impact of HIV and the long-term use of antiretroviral therapy, metabolics are important because they are important risk factors for the development of cardiovascular diseases. The objective of the present study is to evaluate the effect of the supplementation of curcumin, on the oxidation of resting energetic substrates in HIV / AIDS patients. The sample will be composed of adults living with HIV / AIDS on antiretroviral therapy for at least 6 months. Supplements will be made separately for 30 days and will be evaluated before and after the intervention the following parameters: body composition, energy metabolism, biochemical parameters and a structured anamnesis. Food consumption and the level of physical activity of the volunteers will be controlled.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable hiv-infections

Timeline
Completed

Started Sep 2017

Shorter than P25 for not_applicable hiv-infections

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 5, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

September 8, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 24, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2017

Completed
Last Updated

June 21, 2018

Status Verified

June 1, 2018

Enrollment Period

2 months

First QC Date

February 23, 2017

Last Update Submit

June 19, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • The oxidation of energetic substrates evaluation at rest

    The oxidation of energetic substrates evaluation at rest will be performed by indirect calorimetry, a gold standard method for the measurement of energy expenditure, making feasible through the breath by breath technique, weightings to quantify the Caloric expenditure from oxidation fats and carbohydrates. Evaluation will not offer any discomfort since the volunteer will lie flat without moving with a mask fixed on his face, which picks up the breathed and expired gases to be measured by the Respiratory Analyzer - Metalyzer 3B-MICROMED®. To determine oxidation of energetic substrates, subjects will be instructed to sleep approximately for 8 hours the night before, to fast for 12 hours, not to exercise and not to drink caffeinated beverages or alcohol in the 24 hours before the test. Such care should be taken in order to reduce the influence of the thermal effect of food and physical activity on resting metabolism

    10 DAYS

Secondary Outcomes (9)

  • Energy expenditure at rest

    10 DAYS

  • The glycemia evaluation

    10 DAYS

  • The insulin evaluation

    10 DAYS

  • The total cholesterol evalution

    10 DAYS

  • The LDL cholesterol evalution

    10 DAYS

  • +4 more secondary outcomes

Other Outcomes (1)

  • Body composition

    10 DAYS

Study Arms (2)

Curcumin group 1

EXPERIMENTAL

Intervention will be with intake of curcumin, 1000mg per 30 days

Dietary Supplement: Curcumin

Curcumin group 2

PLACEBO COMPARATOR

Intervention will be with placebo intake of curcumin, 1000mg per 30 days

Other: Placebo of Curcumin

Interventions

CurcuminDIETARY_SUPPLEMENT

The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.

Curcumin group 1

The intervention will consist of the placebo administration curcumin for 30 days. The Curcumin placebo will be given in 2 doses of 500mg per day.

Curcumin group 2

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Antiretroviral therapy has been available for at least 6 months, aged 18 years or over.

You may not qualify if:

  • Individuals with endocrine and pregnant disorders will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidade Federal Do Rio Grande Do Norte

Natal, Rio Grande do Norte, 59078970, Brazil

Location

Related Publications (3)

  • Pannacciulli N, Salbe AD, Ortega E, Venti CA, Bogardus C, Krakoff J. The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake. Am J Clin Nutr. 2007 Sep;86(3):625-32. doi: 10.1093/ajcn/86.3.625.

    PMID: 17823426BACKGROUND
  • Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism. 2007 Feb;56(2):289-95. doi: 10.1016/j.metabol.2006.10.012.

    PMID: 17224345BACKGROUND
  • Vassimon HS, de Paula FJ, Machado AA, Monteiro JP, Jordao AA Jr. Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy. Nutrition. 2012 Sep;28(9):912-6. doi: 10.1016/j.nut.2011.12.010. Epub 2012 Apr 13.

    PMID: 22503533BACKGROUND

MeSH Terms

Conditions

HIV Infections

Interventions

Curcumin

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

DiarylheptanoidsHeptanesAlkanesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Study Officials

  • TATIANE AL SILVA, Ms

    UFRN - Avenida Salgado Filho. S/N. Campus Central. Lagoa Nova. Rio Grande do Norte, Brazil

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 23, 2017

First Posted

May 5, 2017

Study Start

September 8, 2017

Primary Completion

October 24, 2017

Study Completion

December 5, 2017

Last Updated

June 21, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

Locations